Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Secutrelvir in Participants With COVID-19 Who Are at High Risk for Progression to Severe Disease

NCT07743580 is registered in ClinicalTrials.gov with Shionogi as lead sponsor.

NCT NCT07743580
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07743580 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Secutrelvir in Participants With COVID-19 Who Are at High Risk for Progression to Severe Disease
Lead sponsor
Shionogi
Phase
Phase 3
Overall status
Recruiting
Start date
September 14, 2026
Completion date
December 31, 2028
Enrollment
2,000 (estimated)
Sites
40

Conditions

As the registry lists them; a condition with its own page is linked.

sars-cov-2